METAVANT SCIENCES
Metavant Sciences is a health care based biopharmaceutical agency that develops therapies for metabolic disorders.
METAVANT SCIENCES
Social Links:
Industry:
Biopharma Biotechnology Health Diagnostics Medical Professional Services
Founded:
2017-01-01
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.metavant.com
Total Employee:
1+
Status:
Active
Contact:
(919) 726-4027
Technology used in webpage:
SPF Euro Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Google Google Cloud MediaElement.js Mimecast Zoom Video Conferencing
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Kato Pharmaceuticals
Kato Pharmaceuticals is a clinical stage Bio-pharmaceutical company dedicated to the development of novel therapies for pathologies.
Official Site Inspections
http://www.metavant.com
- Host name: a904c694c05102f30.awsglobalaccelerator.com
- IP address: 76.223.54.146
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Metavant Sciences"
Metavant Sciences - Crunchbase Company Profile & Funding
Metavant Sciences is a health care based biopharmaceutical agency that develops therapies for metabolic disorders.See details»
Metavant Sciences - LinkedIn
Metavant Sciences is a biopharmaceutical company committed to developing innovative therapies for metabolic disorders. Our current pipeline consists of two investigational drugs for the treatment...See details»
Metavant Sciences Company Profile - Office Locations ... - Craft
Metavant Sciences is a biopharmaceutical company committed to developing therapies for metabolic disorders. Its pipeline consists of two investigational drugs for the treatment of …See details»
Metavant Sciences, Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Metavant Sciences, Inc. of New York, NY. Get the latest business insights from Dun & Bradstreet.See details»
Metavant Sciences - Overview, News & Similar companies
Jul 8, 2019 · View Metavant Sciences (www.metavant.com) location in New York, United States , revenue, industry and description. Find related and similar companies as well as employees …See details»
Metavant Sciences - Contacts, Employees, Board Members
Metavant Sciences is a health care based biopharmaceutical agency that develops therapies for metabolic disorders.See details»
Metavant and Poxel Announce Positive Topline Safety and PK/PD …
Jul 9, 2019 · Metavant aims to initiate a Phase 3 program in patients with type 2 diabetes and chronic kidney disease (CKD) stages 3b/4 in the US and Europe. These results follow two …See details»
Metavant Sciences - Crunchbase
Metavant Sciences is a health care based biopharmaceutical agency that develops therapies for metabolic disorders.See details»
Poxel Provides Update on Metavant Partnership with Imeglimin
Nov 20, 2020 · For strategic reasons, Metavant has decided not to advance Imeglimin into a Phase 3 program; Metavant will actively explore options for a potential out-licensing of …See details»
Roivant licenses Ligand diabetes drug, founds Metavant, as push …
Mar 7, 2018 · Ligand is pocketing $20 million upfront in exchange for the exclusive global rights to LGD-6972, a drug it acquired in its $3.2 million takeover of Metabasis in 2010.See details»
Poxel Regains Imeglimin Rights From Metavant | Poxel SA
Metavant will return all rights to Imeglimin to Poxel, as well as all data, materials, and information, including FDA regulatory filings, related to the program. Metavant is not entitled to any …See details»
Roivant begins latest ‘Vant’ with Ligand deal - BioPharma Dive
Mar 7, 2018 · A licensing deal with Ligand Pharmaceuticals Inc. will kick things off for Metavant Sciences. The deal centers on Ligand's glucagon receptor agonist (GRA) LGD-6972, which is …See details»
Metavant Sciences - Tech Stack, Apps, Patents & Trademarks
Metavant Sciences is a health care based biopharmaceutical agency that develops therapies for metabolic disorders.See details»
Metavant/Poxel prep phase 3 for imeglimin in diabetic kidney …
Jul 9, 2019 · Emboldened by new clinical data, French biotech Poxel and partner Metavant are planning a phase 3 programme in the US and Europe for their diabetic kidney disease therapy …See details»
Poxel may regain diabetes drug rights after Metavant backtracks …
Nov 20, 2020 · Privately held Metavant, a unit of Roivant Sciences Ltd., will attempt to sell the rights to imeglimin to another company within 60 days and will return the rights to Poxel if no …See details»
Poxel Provides Update on Metavant Partnership with Imeglimin
Nov 20, 2020 · Metavant will actively explore options for a potential out-licensing of Imeglimin rights for a period of 60 days; Metavant intends to return Imeglimin rights to Poxel if they are …See details»
Poxel Regains Imeglimin Rights From Metavant - Business Wire
Jan 14, 2021 · Metavant will return all rights to Imeglimin to Poxel, as well as all data, materials, and information, including FDA regulatory filings, related to the program.See details»
Imeglimin Hydrochloride: First Approval - Springer
Imeglimin hydrochloride (TWYMEEG®; hereafter referred to as imeglimin) is an orally administered, first-in-class glimin being developed by Poxel and, in several Asian countries, …See details»
Sumitomo Dainippon Pharma and Roivant Sciences Sign a …
Oct 31, 2019 · Sumitomo Dainippon Pharma will sign an agreement to use the services of Datavant (which has a platform technology for the de-identification and linking of external …See details»
Martin Osterhout - Metavant Sciences, Inc. | LinkedIn
About. Diverse experience in the synthesis, discovery and development of NCEs in Pharma and the… Activity. I am excited to announce that I’ve taken a new role as Sr VP Regulatory Affairs …See details»